Barclays PLC Gh Research PLC Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Gh Research PLC stock. As of the latest transaction made, Barclays PLC holds 5,984 shares of GHRS stock, worth $41,888. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,984

Previous 5,984 -0.0%

Holding current value

$41,888

Previous $40,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$6.69 - $12.49 $93,158 - $173,923	-13,925 Reduced 69.94%	5,984 $40,000
Q2 2024 Aug 14, 2024	SELL	$10.5 - $14.81 $121,705 - $171,662	-11,591 Reduced 36.8%	19,909 $232,000
Q4 2023 Feb 15, 2024	SELL	$5.26 - $11.04 $168,793 - $354,273	-32,090 Reduced 50.46%	31,500 $183,000
Q3 2023 Nov 07, 2023	BUY	$9.8 - $14.15 $308,700 - $445,725	31,500 Added 98.16%	63,590 $640,000
Q2 2022 Aug 12, 2022	SELL	$8.99 - $19.87 $17,997 - $39,779	-2,002 Reduced 5.87%	32,090 $320,000
Q1 2022 May 16, 2022	BUY	$15.48 - $23.98 $527,744 - $817,526	34,092 New	34,092 $624,000

Others Institutions Holding GHRS

# of Institutions

Shares Held

27.8M

Call Options Held

2.8K

Put Options Held

3.8K

View Full List

About GH Research PLC

Ticker GHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,020,800
Market Cap $364M
Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...

More about GHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account